del Rio C, Izazola-Licea JA, Tellez I, Guarner J, Garcia F, Uribe P; International Conference on AIDS.

Int Conf AIDS. 1993 Jun 6-11; 9: 532 (abstract no. PO-B37-2380).

CONASIDA (National AIDS Council), Mexico City, Mexico.

OBJECTIVE. To describe AZT toxicity in asymptomatic HIV-infected mexican patients. METHODS. 205 asymptomatic HIV+ patients receiving 600 mg/d of AZT have been followed for a median time of 6 months. CD4+ cell counts were taken at months 0, 3 and 6. We defined anemia as having < 10 g/dl of hemoglobin (Hb); neutropenia as < 1,000 cells/mm3; and increased AST as more than 95 IU/L. RESULTS. This cohort was predominantly of homo/bisexual men. 21 were women, 4 were infected by transfusion. No patient reported IV drug abuse. 22 patients have been taken AZT before entry. The mean corporal weight was 65.1 kgs (SD = 8.6). 23 patients have been lost and 4 patients have died for HIV-related diseases. At 6 months of follow-up, those who initially had CD4+ cell counts between 200 and 500, had a mean value of 381 and for those with CD4 counts < 200 at entry, 129.8. At time 0 mean Hb was 15.8 g/dl (SD = 1.43), neutrophil average count was 3402 cells/mm3 (SD = 1257) and AST level was 33.8 IU/L (SD = 18). 6 months later, mean Hb was 14.8 g/dl (SD = 1.8), mean neutrophil counts were 2224.4 cells/mm3 (SD = 869.1) and AST level was 39.6 IU/L (SD = 21.9). 46 patients have showed AZT side-effects. The most important manifestations were hematological in 34 patients (10 anemia, 22 neutropenia and 2 both). For anemia, the Incidence was 1.5/Month/person in the first month, 1.28/Month/person in the second and third months, and 0.39/Month/person in the fourth to sixth months. For neutropenia, the Incidence was 5.1/month/person in the first month, 1.53/Month/person in the second and third months and 1.59/month/person in the fourth to sixth months. AZT associated increased AST occurred in 5 patients all of whom were HBsAg+. Thirty-nine had to decrease the dose to 300 mg/d and 7 had to discontinue the drug because of serious toxicity. The 6 Month Cumulative Incidence for anemia was 5.38%, for neutropenia 13.17%, and for increased AST 6.5%. We tested for explanatory factors for toxicity (age, gender, risk factor, corporal weight) via Logistic Regression Analysis. Only base-line corporeal weight was a marginal significant factor. CONCLUSIONS. According to our results, we can observe that the highest probability for toxicity mainly hematological was in the first month of AZT therapy.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• Anemia
• CD4 Lymphocyte Count
• Drug Toxicity
• Female
• HIV Infections
• HIV Seropositivity
• Humans
• Incidence
• Male
• Neutropenia
• Risk Factors
• Zidovudine
• toxicity

Other ID:

• 93336025

UI: 102205403

From Meeting Abstracts